Skip to main content
OpenTrials
Not yet recruiting

NCT Number: NCT07798388

Optimizing Gait Rehabilitation After Stroke

Following a cerebrovascular accident (CVA, also known as a stroke), hemiparesis occurs on the side opposite to the brain injury. This can lead to problems with walking and balance, as well as with arm movements whilst walking. The arm swing serves several important functions whilst walking, such as improving your balance and energy efficiency, and a good arm swing helps to reduce the likelihood of falling if you lose your balance. That is why regaining the ability to walk independently with the best possible arm swing is a key goal during rehabilitation for people who have had a stroke. This ensures that the risk of falling is minimised and that people can resume their daily lives as effectively as possible.

The aim of this study is to gain a better understanding of the abnormalities in arm swing whilst walking in people who have had a stroke, and how we can influence them. To identify these abnormalities, we use surface electromyography, a painless technique that allows us to measure muscle activity whilst walking. To do this, we attach sensors to the muscles whose activity we wish to record.

During this study, we are measuring both people who have had a stroke and healthy adults, in order to detect the effects of a stroke on this muscle activity. The data from the healthy adults will be used to investigate whether we observe different muscle activity in people who have had a stroke.

Not yet recruiting

Trial opening soon.

Get Notified

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

University Hospital Ghent (UZ Gent), Belgium, Ghent, Oost-Vlaanderen, Belgium

Loading trial locations.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Stroke:

  • First-ever ischemic or haemorrhagic stroke
  • Able to walk independently (FAC ≥ 3)
  • Able to walk at least ten minutes
  • No full recovery of the paretic upper limb (FMA-UL < 66)
  • Able to follow simple instructions during the assessment

Exclusion criteria

Stroke:

  • Lesions located in the cerebellum
  • Pre-existing neurological disorders that affect motor function (e.g., Parkinson's disease, multiple sclerosis, dementia, etc.)
  • Pre-existing orthopaedic disorders of the upper and/or lower limbs (e.g., shoulder prosthesis, knee prosthesis, etc.)
  • Inability to provide written informed consent
  • Inability to understand instructions (AbilityQ: verbal < 3/4 and VAS < 3/3)

Exclusion criteria

Healthy:

  • Pre-existing neurological disorders that affect motor function (e.g., Parkinson's disease, multiple sclerosis, dementia, etc.)
  • Pre-existing orthopaedic disorders of the upper and/or lower limbs (e.g., shoulder prosthesis, knee prosthesis, etc.)
  • Injuries of the upper and/or lower limbs that occurred six months or less prior to the time of testing
  • Current pain or ROM limitations at the time of testing
  • Inability to provide written informed consent

Treatment and study plan

VR-feedback application

Other

The VR-feedback application targets the arm swing symmetry during gait. The application provides visual real-time feedback on the amplitude and symmetry of shoulder flexion-extension movements, as well as on excessive elbow flexion.

Primary outcomes

  1. Number of muscle synergies

    Time frame: Baseline, during intervention and immediately after the intervention.

    The number of muscle synergies needed to account for 90% variance in muscle activity measured by surface EMG during walking in stroke survivors compared to healthy controls. Following muscles will be examined:

    • tibialis anterior
    • gastrocnemius lateralis
    • soleus
    • vastus medialis
    • vastus lateralis
    • rectus femoris
    • biceps femoris
    • gluteus medius
    • erector spinae
    • latissimus dorsi
    • anterior deltoid
    • posterior deltoid
    • biceps brachii
    • triceps brachii
  2. Weight of muscle synergies

    Time frame: Baseline, during intervention and immediately after the intervention.

    The number or distribution of muscle weightings within a synergy during walking in stroke survivors compared to healthy controls.

    The distribution of muscle activation averages over one gait cycle measured by surface EMG of following muscles:

    • tibialis anterior
    • gastrocnemius lateralis
    • soleus
    • vastus medialis
    • vastus lateralis
    • rectus femoris
    • biceps femoris
    • gluteus medius
    • erector spinae
    • latissimus dorsi
    • anterior deltoid
    • posterior deltoid
    • biceps brachii
    • triceps brachii
  3. Upper and lower limb kinematics

    Time frame: Baseline, during intervention and immediately after the intervention.

    Movements of the upper limb during walking measured by 3D kinematics.

  4. Physical Activity Enjoyment Scale (PACES)

    Time frame: Single point of assessment immediately after the intervention

    The PACES is a questionnaire on patient enjoyment of physical activity. It consists of 18 items rated on a 7-point Likert scale, with total scores ranging from 18 to 126.

  5. Simulation Task Load Index (SIM-TLX)

    Time frame: Single point of assessment immediately after the intervention

    The SIM-TLX is a questionnaire to assess the workload in simulation and virtual reality. It consists of 10 items rated on a 21-point Likert scale, with total scores ranging from 21 to 210.

  6. List of potential adverse effects

    Time frame: Single point of assessment immediately after the intervention

    A predefined list of potential adverse effects of the VR-feedback application is used to document any experienced adverse effects experienced by participants including an open section for additional unlisted effects.

Secondary outcomes

  1. Fugl-Meyer assessment - Upper and lower limbs

    Time frame: Single point of assessment immediately after the intervention

    The Fugl-Meyer Assessment (FMA) evaluates motor impairment of the upper (FMA-UL) and lower (FMA-LL) extremities. The upper-limb section includes 33 items (maximum score: 66), and the lower limb section includes 17 items (maximum score: 34). Items are scored on a 3-point ordinal scale (0 = cannot perform, 1 = performs partially, 2 = performs fully).

  2. Modified Tardieu Scale

    Time frame: Single point of assessment immediately after the intervention

    The Modified Tardieu Scale (MTS) measures spasticity by assessing the muscle response to passive stretch at different velocities (V1 - V3). It evaluates both the quality of muscle reaction (0 = no resistance to 5 = immovable joint) and the angle of muscle reaction. Full passive ROM (R2) is assessed at slow velocity (V1). The angle at which a catch or clonus occurs (R1) is measured during stretch at V2 (limb falling under gravity) or V3 (quick stretch). The difference (R2 - R1) reflects the dynamic component of spasticity. The muscle groups that may influence the measured muscle activity of the upper and lower limbs will be tested. These include shoulder internal rotators, shoulder extensors, elbow flexors, elbow extensors, hip abductors, hip extensors, hip flexors, knee extensors, knee flexors, and plantar flexors.

  3. Goniometry

    Time frame: Single point of assessment immediately after the intervention

    Goniometry quantifies passive shoulder and elbow ROM. Measurements are obtained using a standard handheld goniometer, following conventional positioning and alignment procedures to ensure reliable documentation of joint mobility.

  4. 10-Meter Walk Test (10MWT)

    Time frame: Single point of assessment immediately after the intervention

    The 10-Meter Walk Test (10MWT) assesses walking capacity. Participants walk a 10-meter distance at a comfortable pace, and the time required to cover the central 10 meters (excluding acceleration and deceleration phases) is recorded. Walking speed (m/s) is calculated as an indicator of functional ambulation.

  5. Kessler Foundation Neglect Assessment Process (KF-NAP)

    Time frame: Single point of assessment immediately after the intervention

    The Kessler Foundation Neglect Assessment Process (KF-NAP) assesses the presence and severity of unilateral neglect during observations of the patient's behavior. It consists of 10 items, each scored from 0 to 3 (0 = no neglect, 1 = mild, with midline crossing only after attention to the right side, 2 = moderate, with clear and consistent left side omissions, and 3 = severe). Total scores range from 0 (indicating no neglect) to 30 (indicating severe neglect). Items 9 and 10, which involve eating tasks, will not be assessed because they cannot be performed in the laboratory setting. The final KF-NAP score will therefore be calculated by averaging the scores of the 8 assessed items and scaling the result to a 0-30 range using the following formula: (sum score / number of scored categories) x 10.

Study contacts

Contact information is provided by the study sponsor or research team.

Gitte Van Cleemput

CONTACT

[email protected]

+3293321243

Sponsors and collaborators

Lead sponsor

University Hospital, Ghent

Other

Collaborators

  • Hasselt University
  • Universiteit Antwerpen
  • University Ghent
  • University Hospital, Antwerp

Registry information

Official study title

Optimizing Gait Rehabilitation After Stroke: Neuromechanical Understanding and the Role of VR Feedback to Improve Arm Swing Functionality

Acronym: NMC

Important dates

Study start
2026
Primary completion
2028
Study completion
2028
First posted
Sep 1, 2026
Registry last updated
Sep 1, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.